Literature DB >> 19356410

High-resolution ultrasound perfusion imaging of therapeutic angiogenesis.

Tuomas T Rissanen1, Petra Korpisalo, Henna Karvinen, Timo Liimatainen, Svetlana Laidinen, Olli H Gröhn, Seppo Ylä-Herttuala.   

Abstract

OBJECTIVES: The purpose of this study was to test the feasibility of contrast pulse sequence (CPS) ultrasound imaging for high-resolution perfusion imaging after gene transfer (GT) for therapeutic angiogenesis.
BACKGROUND: Imaging modalities capable of accurate and feasible perfusion measurement are essential for the preclinical and clinical development of therapeutic angiogenesis. However, current methods suffer from compromises between spatial and temporal resolution and sensitivity. Contrast pulse sequence ultrasound is a recently developed real-time perfusion imaging method that generates high-contrast agent-to-tissue specificity and spatial resolution.
METHODS: Contrast pulse sequence ultrasound was used to noninvasively assess parameters of blood flow 6 days after adenoviral vascular endothelial growth factor (AdVEGF) GT in rabbit and mouse hind limbs with bolus intravenous injection of a microbubble contrast medium. Blood volume, mean transit time, perfusion, and time to the arrival of the contrast bolus were calculated with the gamma variate function. Contrast-enhanced power Doppler ultrasound (CEU), dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), and histological capillary measurements were used as reference methods.
RESULTS: Blood volume and perfusion increased over 40- and 20-fold, respectively, 6 days after AdVEGF GT in rabbit skeletal muscles. Perfusion values measured with CPS correlated well with those obtained with CEU (r = 0.975) and DCE-MRI (r = 0.854). However, CPS provided superior spatial and temporal resolution showing blood flow in vessels of only 10 to 20 mum in diameter. Contrast pulse sequence ultrasound was also feasible for imaging of therapeutic angiogenesis in mouse hind limbs both at the arterial and capillary levels. The CPS ultrasound revealed that AdVEGF mainly induces angiogenesis in adipose tissue rather than in the skeletal muscle of mouse hind limbs.
CONCLUSIONS: Contrast pulse sequence ultrasound is an efficient and accurate noninvasive real-time perfusion imaging modality in small laboratory animals and also offers a means for the assessment of muscle perfusion in future clinical trials of therapeutic angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19356410     DOI: 10.1016/j.jcmg.2007.10.009

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  19 in total

1.  Inhibitor of differentiation-3 mediates high fat diet-induced visceral fat expansion.

Authors:  Alexis Cutchins; Daniel B Harmon; Jennifer L Kirby; Amanda C Doran; Stephanie N Oldham; Marcus Skaflen; Alexander L Klibanov; Nahum Meller; Susanna R Keller; James Garmey; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-10       Impact factor: 8.311

2.  Robust quantification of microvascular transit times via linear dynamical systems using two-photon fluorescence microscopy data.

Authors:  Lakshminarayan V Chinta; Liis Lindvere; Bojana Stefanovic
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-20       Impact factor: 6.200

3.  Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US.

Authors:  Nirupama Deshpande; Amelie M Lutz; Ying Ren; Kira Foygel; Lu Tian; Michel Schneider; Reetesh Pai; Pankaj J Pasricha; Jürgen K Willmann
Journal:  Radiology       Date:  2011-11-04       Impact factor: 11.105

4.  Pixel-based approach to assess contrast-enhanced ultrasound kinetics parameters for differential diagnosis of rheumatoid arthritis.

Authors:  Gaia Rizzo; Bernd Raffeiner; Alessandro Coran; Luca Ciprian; Ugo Fiocco; Costantino Botsios; Roberto Stramare; Enrico Grisan
Journal:  J Med Imaging (Bellingham)       Date:  2015-09-11

5.  High Resolution Ultrasound Superharmonic Perfusion Imaging: In Vivo Feasibility and Quantification of Dynamic Contrast-Enhanced Acoustic Angiography.

Authors:  Brooks D Lindsey; Sarah E Shelton; K Heath Martin; Kathryn A Ozgun; Juan D Rojas; F Stuart Foster; Paul A Dayton
Journal:  Ann Biomed Eng       Date:  2016-11-10       Impact factor: 3.934

6.  Parametric contrast-enhanced ultrasound as an early predictor of radiation-based therapeutic response for lymph node metastases of nasopharyngeal carcinoma.

Authors:  Zhimin Ye; Pintong Huang; Xiaofeng Zhou; Qian Huang; Qiongge Hu; Yongjie Shui; Li Shen; Enyin Lai; Qichun Wei
Journal:  Mol Clin Oncol       Date:  2014-06-27

7.  Limited value of digital subtraction angiography in the evaluation of cell-based therapy in patients with limb ischemia.

Authors:  Robert B van Tongeren; Jaap F Hamming; Saskia le Cessie; Arian R van Erkel; J Hajo van Bockel
Journal:  Int J Cardiovasc Imaging       Date:  2009-09-16       Impact factor: 2.357

8.  Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels.

Authors:  Petra Korpisalo; Henna Karvinen; Tuomas T Rissanen; Johanna Kilpijoki; Varpu Marjomäki; Peter Baluk; Donald M McDonald; Yihai Cao; Ulf Eriksson; Kari Alitalo; Seppo Ylä-Herttuala
Journal:  Circ Res       Date:  2008-10-02       Impact factor: 17.367

9.  Perfusion estimation using contrast-enhanced 3-dimensional subharmonic ultrasound imaging: an in vivo study.

Authors:  Anush Sridharan; John R Eisenbrey; Ji-Bin Liu; Priscilla Machado; Valgerdur G Halldorsdottir; Jaydev K Dave; Hongjia Zhao; Yu He; Suhyun Park; Scott Dianis; Kirk Wallace; Kai E Thomenius; Flemming Forsberg
Journal:  Invest Radiol       Date:  2013-09       Impact factor: 6.016

10.  First-in-Human Study of Acoustic Angiography in the Breast and Peripheral Vasculature.

Authors:  Sarah E Shelton; Brooks D Lindsey; Paul A Dayton; Yueh Z Lee
Journal:  Ultrasound Med Biol       Date:  2017-10-02       Impact factor: 2.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.